報價延遲最少15分鐘:2025/01/11 11:27 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.1 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-7.22/-1.92
|
|
企業價值
27.58M
|
| 資產負債 |
|
每股賬面淨值
0.32
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 11:27 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy. |